AbbVie Inc. (NYSE:ABBV) is a hot topic among investors, with shares up 21% this year. Carillon Eagle Growth & Income Fund noted ABBV’s weakness in the second quarter, attributing it to industry underperformance due to Trump administration policies. Some suggest other AI stocks may offer better returns than ABBV.

Read more at Yahoo Finance: Analyst on AbbVie (ABBV): ‘Stay Long’